scholarly article | Q13442814 |
P50 | author | Charles Jayne | Q88797848 |
P2093 | author name string | Francisco Velazquez | |
Robert Chase | |||
Sathesh Bhat | |||
Sony Agrawal | |||
Srikanth Venkatraman | |||
Hubert Josien | |||
Jin Wu | |||
Murali Rajagopalan | |||
Thomas Bara | |||
Shouwu Miao | |||
Yan Xia | |||
Unmesh Shah | |||
John Howe | |||
Rebecca T Ruck | |||
Patrick Pinto | |||
Samuel Chackalamannil | |||
Yongxin Han | |||
Ian W Davies | |||
Santhosh F Neelamkavil | |||
Stacia Kargman | |||
Donald Sperbeck | |||
Andrew Nolting | |||
Zhuyan Guo | |||
Vincent J Colandrea | |||
Austin Chen | |||
Mark Cartwright | |||
Aileen Soriano | |||
Chad Bennett | |||
Nicole Buist | |||
Keith Eagen | |||
Martin Clasby | |||
Dipshikha Biswas | |||
Duane Burnette | |||
Karen Marcantonio | |||
Linda Brockunier | |||
Mariappan Chelliah | |||
Randy Miller | |||
P2860 | cites work | Sofosbuvir, a Significant Paradigm Change in HCV Treatment | Q26781773 |
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection | Q27644511 | ||
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease | Q27684622 | ||
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants | Q34276394 | ||
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre | Q34451707 | ||
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection | Q38522622 | ||
Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease | Q39658512 | ||
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors | Q39782827 | ||
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325. | Q42155851 | ||
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection | Q42235540 | ||
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor | Q42242164 | ||
Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution. | Q42712427 | ||
P433 | issue | 1 | |
P304 | page(s) | 111-116 | |
P577 | publication date | 2015-12-22 | |
P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
P1476 | title | Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor | |
P478 | volume | 7 |
Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
Q53622320 | Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors. |
Q40618808 | Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. |
Q92126689 | Targeting HIV/HCV Coinfection Using a Machine Learning-Based Multiple Quantitative Structure-Activity Relationships (Multiple QSAR) Method |
Q53755762 | The utilization of spirocyclic scaffolds in novel drug discovery. |
Search more.